Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zocor To Get Special Medco Attention: Market Share Protections Set In IPO

Executive Summary

Merck's Zocor protection program for the spin-off of MedcoHealth Solutions includes an incentive for Medco to keep the cholesterol agent at a market share level tied to its 2001 position

You may also be interested in...



PBM “Transparency” Defined In Medco Settlement

The Medco injunction requires the pharmacy benefit management company to disclose the existence of rebate relationships in its communications to clients, physicians and patients

PBM “Transparency” Defined In Medco Settlement

The Medco injunction requires the pharmacy benefit management company to disclose the existence of rebate relationships in its communications to clients, physicians and patients

Merck/Medco Rebate Deal Gives Merck Control Of New Managed Care Tools

Merck's rebate agreement with Medco will give the manufacturer a measure of control over moves by managed care companies to adopt innovative cost control tools

Related Content

UsernamePublicRestriction

Register

PS039762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel